Medinol’s Nirflex
This article was originally published in The Gray Sheet
Executive Summary
Israeli firm's next generation stent is set to enter estimated $500 mil. European market following CE mark approval, announced March 14. The launch "marks the first time Medinol will independently bring a stent mounted on its own delivery system to market," the firm notes. Medinol recently announced its intention to terminate its exclusive, worldwide NIR coronary stent supply agreement with Boston Scientific (1"The Gray Sheet" March 4, 2002, In Brief)...